Company intelligence / Profile preview

Equation

Cambridge, Massachusetts, United States

Ownership: Private
Employees: ~25
Development stage: Other

Overview

Equation is a biotechnology company dedicated to developing transformative precision medicines for heart failure and other cardiovascular diseases. Founded by Dr. Mark Fishman, the former President of the Novartis Institutes for BioMedical Research, the company leverages genetic insights and advanced biological modeling to target the underlying causes of cardiac dysfunction. Equation aims to move beyond generic treatments for heart failure toward therapies tailored to specific genetic and molecular profiles. The company is currently in the pre-clinical stage and is backed by prominent life science investors including GV and Casdin Capital.

Therapeutic areas: Cardiovascular
Modalities: Gene therapySmall molecule
Industry: Biotech

Beyond the preview

Go deeper on Equation.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Equation.

Explore the full profile